Evolving treatment algorithms in crohn’s disease

Andrew Wisniewski, Silvio Danese, Laurent peyrin-Biroulet

Research output: Contribution to journalReview article

Abstract

Crohn’s disease (CD) is a chronic, disabling and destructive condition. Half of the patients will develop some bowel damage (stricture, fistula and/or abscess). Current therapeutic strategies failed to alter its natural history. Treatment of CD has evolved over a quarter of a century from a linear sequence of treatment intensification to a complex algorithm focused on individualized patient care by looking beyond symptoms. A tight monitoring of objective signs of inflammation and a treat to target approach are probably the only way to change patients’ life and disease course. We now seek to optimize our therapeutic tools according to patient profile, disease phenotype and the unique pharmacodynamics that ensues. This article explores the evolving concepts in assessing disease severity, selecting rigorous treatment end-targets, initiating an effective therapeutic therapy, and managing secondary loss of response.

Original languageEnglish
JournalCurrent Drug Targets
Volume17
Issue number13
DOIs
Publication statusPublished - May 29 2016

Fingerprint

Crohn Disease
Pharmacodynamics
Therapeutics
Natural History
Abscess
Fistula
Patient Care
Pathologic Constriction
Monitoring
Inflammation
Phenotype

Keywords

  • Anti-tnf
  • Crohn’s disease
  • Treat to target
  • Treatment algorithm

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Evolving treatment algorithms in crohn’s disease. / Wisniewski, Andrew; Danese, Silvio; peyrin-Biroulet, Laurent.

In: Current Drug Targets, Vol. 17, No. 13, 29.05.2016.

Research output: Contribution to journalReview article

Wisniewski, Andrew ; Danese, Silvio ; peyrin-Biroulet, Laurent. / Evolving treatment algorithms in crohn’s disease. In: Current Drug Targets. 2016 ; Vol. 17, No. 13.
@article{bbb815315d7e4058a7ddad398fda0f24,
title = "Evolving treatment algorithms in crohn’s disease",
abstract = "Crohn’s disease (CD) is a chronic, disabling and destructive condition. Half of the patients will develop some bowel damage (stricture, fistula and/or abscess). Current therapeutic strategies failed to alter its natural history. Treatment of CD has evolved over a quarter of a century from a linear sequence of treatment intensification to a complex algorithm focused on individualized patient care by looking beyond symptoms. A tight monitoring of objective signs of inflammation and a treat to target approach are probably the only way to change patients’ life and disease course. We now seek to optimize our therapeutic tools according to patient profile, disease phenotype and the unique pharmacodynamics that ensues. This article explores the evolving concepts in assessing disease severity, selecting rigorous treatment end-targets, initiating an effective therapeutic therapy, and managing secondary loss of response.",
keywords = "Anti-tnf, Crohn’s disease, Treat to target, Treatment algorithm",
author = "Andrew Wisniewski and Silvio Danese and Laurent peyrin-Biroulet",
year = "2016",
month = "5",
day = "29",
doi = "10.2174/1389450117666160607075557",
language = "English",
volume = "17",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Evolving treatment algorithms in crohn’s disease

AU - Wisniewski, Andrew

AU - Danese, Silvio

AU - peyrin-Biroulet, Laurent

PY - 2016/5/29

Y1 - 2016/5/29

N2 - Crohn’s disease (CD) is a chronic, disabling and destructive condition. Half of the patients will develop some bowel damage (stricture, fistula and/or abscess). Current therapeutic strategies failed to alter its natural history. Treatment of CD has evolved over a quarter of a century from a linear sequence of treatment intensification to a complex algorithm focused on individualized patient care by looking beyond symptoms. A tight monitoring of objective signs of inflammation and a treat to target approach are probably the only way to change patients’ life and disease course. We now seek to optimize our therapeutic tools according to patient profile, disease phenotype and the unique pharmacodynamics that ensues. This article explores the evolving concepts in assessing disease severity, selecting rigorous treatment end-targets, initiating an effective therapeutic therapy, and managing secondary loss of response.

AB - Crohn’s disease (CD) is a chronic, disabling and destructive condition. Half of the patients will develop some bowel damage (stricture, fistula and/or abscess). Current therapeutic strategies failed to alter its natural history. Treatment of CD has evolved over a quarter of a century from a linear sequence of treatment intensification to a complex algorithm focused on individualized patient care by looking beyond symptoms. A tight monitoring of objective signs of inflammation and a treat to target approach are probably the only way to change patients’ life and disease course. We now seek to optimize our therapeutic tools according to patient profile, disease phenotype and the unique pharmacodynamics that ensues. This article explores the evolving concepts in assessing disease severity, selecting rigorous treatment end-targets, initiating an effective therapeutic therapy, and managing secondary loss of response.

KW - Anti-tnf

KW - Crohn’s disease

KW - Treat to target

KW - Treatment algorithm

UR - http://www.scopus.com/inward/record.url?scp=85010670061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010670061&partnerID=8YFLogxK

U2 - 10.2174/1389450117666160607075557

DO - 10.2174/1389450117666160607075557

M3 - Review article

AN - SCOPUS:85010670061

VL - 17

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 13

ER -